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Allogeneic Whole Pancreas Transplantation in Insulin-Dependent
Diabetes Mellitus

Jose Goldman, MD, PhD,* Heung K. Oh, MD,+ Marc G. Webb, MD,*
Martin Mozes, MD,* Nancy Tlirza, RN,* Warren L. Kupin, MD,§
K. K. Venkat, MD,§ and Ramon del Busto, MDll

A clinical whole organ pancreas transplantation program for patients with insulin-dependent
diabetes mellitus complicated hy end-stage renal disease was initiated at Henry Ford Hospital
in 1987. Five patients have received pancreatic allografts after a previous kidney transplant (phase
I), and six patients had simultaneous pancreas-kidney transplants (phase 2). Ten patients had
functioning pancreatic grafts after surgery, and all of them had normal carbohydrate tolerance
with appropriate plasma free insulin responses to an oral glucose tolerance test three months
after transplantation. As long as 28 months postsurgery six patients remained free of insulin
requiremenls; however, one patient rejected the pancreatic allograft, and three patients died hecause
of cytomegalovirus pneumonia. Two ofthe latter patients hadfunction ing pancreatic allografts at the
time of their demise. These results compare favorably with those of the International Pancreas
Transplant Registry which reflects the world experience. Pancreas transplantation is a unique
experimental treatment with the potential of restoring euglycemia and improving the prognosis of
insulin-dependent diabetic patients. (Henry Ford Ho.sp Med J 1990;38:246-51}

T

he availability of insulin for therapy of diabetes mellitus
resulted in araarkedprolongation of patient survival after
the hormone was discovered in 1921. However, maintaining euglyceraia and preventingraicrovascularcoraplications has been
a more elusive goal using conventional insulin therapy. Pancreas transplantation currentiy offers the only therapeutic intervention for insulin-dependent diabetes mellitus (IDDM) that
can provide persistent euglycemia, although continuous immunosuppression is required to prevent graft rejection. The risks
attached to the imraunosuppressive treatraent are considerable
and have limited the application of pancreas transplantation to
diabetic patients who are previous or siraultaneous recipients of
kidney grafts. Because such patients frequently present other diabetic coraplications in addition to their nephropathy, pancreas
transplantation has been advocated at a stage in the progression
of diabetes earlier than end-stage nephropathy, in the hope that
the mortality and serious morbidity associated with advanced
neurovascular complicarions will be prevented (1). In IDDM
patients with pancreatic allografts, the long-term effects of euglycemia on theraicrovascularcoraplications of the disease remain to be established, but preliminary studies have shown encouraging results (2-6).
Whole organ pancreas transplantation in IDDM has been
performed worldwide with increasing frequency and improving
patient and functional graft survival rates (7). A number of surgical techniques have been used, including duct-injected segmental pancreas allografts, Roux-en-Y jejunostomy enteric
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drainage with either segraental or whole pancreas transplants,
and urinary drainage with whole pancreas allografts. Eitherthe
latter approach or whole organ allograft with duodenocystostomy for exocrine diversion combined with a renal transplant
(Fig 1) is the currently preferred surgical procedure because of
minimal surgical coraplications (8). The pancreas transplantarion prograra was established at Henry Ford Hospital in May
1987. Phase I (pancreas transplantation in patients with functioning kidney allografts) and phase 2 (siraultaneous transplantation of kidney and pancreas from a single donor) clinical pancreas transplants have been performed using the surgical technique of urinary bladder diversion of exocrine pancreas secretion. This report presents the results of the pancreas transplantation prograra at Henry Ford Hospital.

Materials and Methods
Candidates for pancreas transplantation were selected by ^
multidisciplinary team. Pretransplant evaluation included asSubmitted for publication: March 14. 1990,
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pig I Surgical scheme of the combined kidney-pancreas
transplantation with duodenocystostomy for pancreatic exocrine drainage. (From D'Alessandro AM. Stratta RJ, Sollinger
HW,KalayogluM, PlrschJD,Belzer FO. Use of UW solution in
pancreas transplantation. Diabetes 1989:38]suppl l]:7-9. Reproduced with permission of the American Diabetes Association, Inc.)

sessments by a psychiatrist, social worker, and chaplain. The
candidates were patients with IDDM coraplicated by diabetic
nephropathy and end-stage renal disease who either had a previous, stable kidney allograft or were scheduled to receive a simultaneous kidney and pancreas allograft. Criteria for exclusion
were coronary artery disease (angina pectoris and congestive
heart failure) and peripheral occlusive vascular disease (intermittent claudicarion, ischeraic foot ulcer and amputation). A total of 11 patients have received pancreas allografts; five patients
were forraer recipients of kidney allografts (phase 1), and six
patients received siraultaneous pancreas and kidney transplants
(phase 2). All patients had oral glucose tolerance tests with assessment of plasraa glucose and free insulin levels before and
three months after surgery. Plasraa free insulin concentrations
were measured using a double antibody radioimraunoassay according to Kuzuya et al (9). The pancreas transplantation program was approved by the Institutional Review Board and informed consent was obtained frora all patients.
The quadruple iraraunosuppressive protocol used in the first
five patients consisted of Minnesota antilyraphoblast globulin
20 mg/kg/day for ten days, cyclosporine A 4 mg/kg/day intravenously followed by 10rag/kg/dayorally, methylprednisolone
0-5 mg/kg/day orally, and azathioprine 1.5 rag/kg/day orally.
TTie subsequent six patients received for imraunosuppression
3n induction with OKT3 (orthoclone,raonoclonalantibody) 5
nig/day for ten days followed by cyclosporine A 10 mg/kg/day
orally. These changes in the imraunosuppressive protocol were
introduced to minimize cyclosporine-related renal toxicity while
^he kidney graft was recovering frora insults related to organ
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Fig 2—Glycemic profiles in response to an oral glucose tolerance test performed before and three months after a technically
successful whole pancreas transplantation in insulin-dependent
diabetic patients .Data are shown as mean ±SE (N = 11). Overall differences between glycemic profiles before and after pancreas transplantation were highly significant by a two-tailed,
paired Student t test using the Bonferroni adjustment (P <
0.003) (35).
harvesting, preservation, and reperfusion. Diagnosis of rejection was based on urinary amylase levels, urine pH, and fasting
blood glucose measureraents. Pertusion scans with ^'^™technetiura, arteriography, andraagneticresonance iraaging were utilized to aid in the diagnosis of pancreatic graft rejection. Criteria
used for the diagnosis of rejection were a decrease in urinary
araylase excretion of 50% orraoreor an absolute araylase level
of 3,000 lU/L. Outpatient surveillance for rejection was done
via urine pH testing by a dipstickraethod.A drop in pH of 1.5
units frora previous values was an indication for further evaluation of pancreatic graft dysfunction. Loss of endocrine graft
function was established by two consecutive plasma glucose
levels of 140 mg/dL or higher (10).

Results and Discussion
Pretransplant characteristics of the recipients are listed in Table 1, and donor information is given in Table 2. The organ recipients (three men and eight woraen) ranged in age frora 17 to
44 years, and theirraeanduration of diabetes was 22.2 years.
Metabolic control in most patients was suboptimal prior to surgery, and they all had significant diabericraicrovascularcoraplications, sorae very severe. Organ donors ranged in age from 13
to 44 years (raean 26.8 years). All but one of the transplanted
pancreatic allografts had good initial function, and no insulin
was required postsurgery in any patient. Table 3 shows the results and complications after a follow-up to 28 raonths. The
raean glycemic profile during oral glucose tolerance tests perforraed before and three raonths after pancreas transplantation
is given in Fig 2. Carbohydrate tolerance was norraalized by the
functioning grafts. Free insulin levels corresponding to these
studies (Fig 3) rose markedly in response to the oral glucose
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Table 1
Pretransplant Characteristics of Diabetic Patients
Duration of

Insulin

Hb A,(,

Diabetes (yrs)

Dosage (U/d)

(%)

1/35/M

33

52

11.2

2/33/F

23

3/44/F

22

52

4/3I/F

24

25

5/31/F

21

35

6/27/F

20

40

13.9

7/31/F

24

30

11,9

8/27/M

21

38

11.4

9/24/M

20

64

8,4

10/31/F

19

11/17/F

17

Patient
No/Age/Sex

Secondary Complications
S retinopathy, right eye blind,
S polyneuropathy, ESRD S/P LRT 12/83
S gastroparesis, S polyneuropathy.
S retinopathy. ESRD S/P LRT 5/75
S gastroparesis, S polyneuropathy,
S retinopathy, pancreatic insufficiency,
ESRD S/P CAD Tx 3/86
M retinopathy, M polyneuropathy,
ESRD S/P LRT 11/82
S retinopathy, S gastroparesis,
S polyneuropathy. ESRD, on dialysis
M retinopathy, M polyneuropathy,
osteomyelitis, ESRD, on dialysis
M retinopathy, S gastroparesis,
M polyneuropathy, osteomyelitis,
ESRD, on dialysis
M retinopathy, M polyneuropathy,
S gastroparesis. ESRD S/P LRT 4/87
Blindness, M polyneuropathy,
ESRD on dialysis
M retinopathy, S polyneuropathy
osteomyelitis, ESRD, on dialysis
Mild polyneuropathy, blindness,
mild gastroparesis, approaching ESRD

14,1

11.8

15.0
62
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Hb A^. = hemoglobin Aj^^. S = .severe. M = moderale. ESRD - end-stage renal disease. S/P - spleen/pancreas. LRT = living
related (renal) transplant, CADTx = cadaver (renal) transplant.

Table 2
Pancreas Donor and Transplantation
Donor Informalion

Patien Donor Cause of err
No
Age
Death
(hrs)

Transplantation

Pres
Solution

Liv/Pan
Harvest

Pancreas
Only

Immediale
P-i-K

Function

Hospital
Stay (days)

1

23

MVA

2,5

Belzer's

No

V

Yes

23

2

28

GSW

3,0

Belzer's

Nl)

V

Yes

10.^

3

26

MVA

4.0

Belzer's

No

V

Yes

2S

4

42

CVA

3,0

Belzer's

No

V

Yes

24

44

MVA

4,0

Belzer's

No

V

Yes

23

6

24

MVA

5,0

Belzer's

No

V

Yes

44

7
9
10

17
28
26
24

MVA
CVA
CVA
GSW

1,5
6.0
5.0
5,6

Belzer's
Belzer's
Belzer's
Belzer's

Yes
Yes
No
Yes

V

x

V
V

Yes
Yes
Yes
Yes

26
30
21
29

11

13

MVA

5.0

UW

Yes

V

No

41

V

Complications
Rejection episode.
UTI/pancreatilis
Rejection episode,
CMV pneumonia,
chronic rejection
Orthostatic
hypotension
Rejection episode,
seizure, clot
retention
HUS, clol
retention
Rejection episode,
transplant
nephrectomy
Rejection episode
Rejection episode, UTI
Clot retention
Clot retention,
metabolic acidosis
Vascular thrombosis

CIT = cold ischemia time, Pres = preservation, Liv/Pan = liver/pancreas, P+K = pancreas and kidney, MVA = motor vehicle accident, GSW = gunshot
wound, CVA = cerebrovascular accident, UW = preservation solution UW, V = check mark on type of performed surgery, UTI = urinary tract infection,
CMV = cytomegalovirus, HUS = hemolytic uremic syndrome.
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jjiallerige. Such a response is expected in patients with functionpancreatic allografts who have a degree of insulin resistance
jjcoudary to the steroids used for iraraunosuppression. Norraalj^tion of metabolic control during the same posttransplantation
^riod is further deraonstrated by norraal hemoglobin A|^, levels
0ig4). Of the 11 whole organ pancreas transplants performed
^jth the duodenocystostomy technique described by Sollinger
j[ jl (11), ten of the procedures were technically successful (indicated by postoperative functioning grafts) and one graft was
Ejt by chronic rejection after the patient acquired cytomegalovirus (CMV) pneuraonia and iraraunosuppressive therapy was
0thdrawn. Two recipients who succurabed frora CMV infecflon at three and 16raonths,respecrively, had norraally functioning pancreatic allografts.
The International Pancreas Transplant Registry recorded
1394 pancreas transplants performed frora December 1966 to
March 1988 (12). These data reveal progressive improveraent in
graft functional survival rates, with a one-year average survival
rate of 61% of the technically successful pancreas transplants
performed frora 1983 to 1988. Combined use of cyclosporine A
and azathioprine was raore effective than any single iraraunosuppressive protocol in maintaining pancreatic allograft function. One-year functional graft survival rate for simultaneous
pancreas-kidney transplants (53%) was better than for those
with a preceding kidney transplant (40%) or no kidney transplant at all (32%). Corresponding one-year patient survival rates
were 90%, 88%, and 77%.
Our experience with the first 11 pancreas transplants compares favorably with the results listed in the Intemational Pancreas Transplant Registry, but CMV infection remains a raajor
concem for the recipients. Recommendedraeasuresto reduce
the ominous complication of CMV infection include matching

CMV antibody-negative donors with CMV antibody-negative
recipients, the use of CMV-negative blood products, and the
prophylactic adrainistration of anti-CMV iraraunoglobulin.
The immunosuppression protocols cunently in use have been
optimized only to prevent pancreas allograft rejection as indicated by parameters such as urinary amylase or pH andraaybe
less effective in arresring pancrearic beta cell autoimraunity.
The postulated autoiraraune pathogenesis of IDDM (13-15) is
likely to continue operating after a pancreas transplant and may
lead to progressive loss of both beta cells and insulin secretory
reserve in the pancreas allografts. Thus, recunence of I DDM has
been observed in recipients of segmental pancreas grafts frora a
raonozygotic twin donor (16,17). The possible irapact of currently used immunosuppressive protocols on the autoiraraune
destruction of pancrearic beta cells is unknown. However, attempts to arrest pancreatic beta cell loss in newly diagnosed
IDDM patients have been only partially and transientiy successful (18-20). Further studies are needed in the context of preserving pancreas graft function and preventing graft iraraunological
rejection.
Islet cell transplantation and transfection of spliced insulincoding segments of the genome into nonbeta cells are potential
altemative approaches for restoring adequate insulin secretion
in IDDM. The former intervention requires the availability of a
sufficient mass of pancreatic islets and the need to prevent the
iraraunologic rejection. Utilizingraultiplepancreases frora inbred aniraal donors has perraitted successful isografting of isolated pancreatic islets in aniraal models, but for obvious reasons
this is not feasible in human diabetics. Transplantation of dispersed pancreatic preparations without islet purification has resulted in increased yields of islettissueand reversion of IDDM
in dogs (21,22). Success in applying this procedure to patients—

Table 3
Resuits of Piiase 1 and Phase 2 Pancreas Transplants
Patient
No

Follow-up
FES
(monlhs)
(mg/dL)

SCr
(mg/dL)

U Amylase
(U/L)

UpH

Complications

Outcome

Urinary retention
CMV pneumonia,
chronic rejection
BKA
Osteomyelitis. UTI,
pseudomembranous
colitis, CMV infection
HUS. CMV pneumonia

Well
Died 25 months
posttransplant
Well
Died 16 months
posttransplant

1
2

28
6

92
173

1.5
0.9

104.500
16

7,5
6.,s

3
4

23
16

72
79

1.1
1.2

94,736
93,700

K.O
7.0

5

3

107

6.0

65.900

7.5

6

1 1

85

12,4

62,400

8.5

7

7

S4

0.9

38,000

7.0

8
9
10
11

6
5
4
1

103
92
85
135

1.4
2.1
l.l
2.2

57,702
46,852
258,816
0

7.0
7.5
S.O
5.5

Transplant nephrectomy,
CVA
Osteomyelitis, Iransmetatarsal amputation,
urine leakage, Iransplanl
pancreatectomy
Rejection episode
Clol retention
Metabolic acidosis
Thrombosis of vessels

Died 3 monlhs
posttransplant
Well
Diabetic

Well
Well
Well
Diabetic

FBS - fasting blood sugar, SCr = serum creatinine, U = urine, BKA = below-knee amputation, UTI = urinary tract infection, CMV = cytomegalovirus,
CVA = cerebral vascular accidenl.
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Pre-Pancreas Transplantation

Hb Afc Levels

14

Post-Pancreas Transplantation

12
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10
8
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Fig 4—Comparison of mean hemoglobin Aj^ levels before arul
three months after technically successful whole panci-eas tramplantation (N = 10).
1

2

Time (h)

Fig 3—Mean plasma free insulin concentrations corresponding to the oral glucose tolerance tests summarized in Fig 2.
Data are shown as mean + SE (N = 11). Statistical anaiy.sts performed as described in the caption to Fig 2 revealed highly significant differences between the curves describing the plasma
free insulin responses to an oral glucose challenge before and
after pancreas transplantation (P < 0.006).

autotransplantation of islet cells after a near-total pancreatectomy for intractable pain of chronic pancreatitis—has been limited by low islet yields from fibrotic pancreatic tissue (23-26)
and autoiraraune recunence of the diabetic state (27). An interesting new attempt to obtain insulin-secreting cells is the transfection of total genomic DNA or spliced DNA fragments containing the insulin coding gene(s) and regulatory elements into
nonbeta cells (28,29), but these approaches have been limited by
problems with inefficient transfection rates and instability of the
genetic constructs. Further research into these areas raay help
solve the problems of insufficient yields of insulin-secreting
cells and immune rejection by converting in vitro nonbeta cells
of the recipient into insulin-secretory cells through transfection
of insulin genes prior to grafting.
Developraent of new iraraunosuppressive drugs, raany currentiy at different stages of clinical trials, is an encouraging step
toward iraproved prevention of allograft rejection. These drugs
include FK506 and monoclonal antibodies to the interleukin-2
receptor. FK506 has a mechanism of action similar to that of cyclosporine A but hasrauchgreater iraraunosuppressive potency
and no nephrotoxicity (30). Cyclosporine A and FK506 produce
immunosuppression by inhibiting transcription of early T-cell
activation genes (e.g., interleukins-2, -3, and -4, interferon-y,
and granulocyte-raacrophage colony stiraulating factor) (31).
These two therapeutic agents also bind to proteins that are
peptidyl-prolyl-cis-trans-isomerases (rotamases), thereby inhibiting their catalytic activity (32). Elucidation of these mechanisras raay help in the design of more potent iramunosuppres-
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sive agents. Antibodies against the interleukin-2 receptor block
the binding of interleukin-2, preventing the proliferation of f
cells that participate in allograft rejection and in certain autoiraraune diseases (33). Anti-interleukin-2-receptor therapy is effective in preventing rejection of renal grafts (34).
In conclusion, the results of the pancreas transplantation program at Henry Ford Hospital corapare favorably to those of the
world experience recorded in the Intemational Pancreas Transplant Registry. Corabined renal and pancreas transplantation
frora a single donor is the currently preferred procedure. The
significant iraproveraent in the results of whole organ and segraental pancreas transplantation, in terms of both patient and
functional graft survival, indicates that this approach, although
still experimental, represents a potential cure of IDDM.
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